2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.03B.05 Construction and Validation of a Prognostic Model Using Loratadine-Related Genes in NSCLC Patient with Tumor Microenvironment.

EP.03B.05 Construction and Validation of a Prognostic Model Using Loratadine-Related Genes in NSCLC Patient with Tumor Microenvironment.

Back to course

Pdf Summary

This study investigates the link between loratadine use and the survival of lung adenocarcinoma (LUAD) patients, developing a prognostic model based on gene expression and clinical features. Researchers established a risk score formula incorporating five genes: ABCC2, NUPR1, KCNH2, ABCB1, and NR0B2. This model categorizes LUAD patients into high-risk and low-risk groups with varying survival rates, validated through Kaplan-Meier curves and ROC analysis, showing AUCs of 0.677, 0.640, and 0.644 for 1, 3, and 5 years, respectively. Multivariate regression confirmed pathological subtyping and the risk model as independent prognostic factors.<br /><br />Immune profiling demonstrated different expressions of immune cells and checkpoints between the high and low-risk groups, with the low-risk group exhibiting a more favorable immune environment. In vivo experiments reinforced these findings. Immunohistochemistry showed significant differences in the expression of KCNH2 and NR0B2 genes between patients treated with loratadine and those not receiving it, suggesting loratadine might improve LUAD survival through these genes' expression.<br /><br />Using LASSO Cox regression from the Cancer Genome Atlas (TCGA) cohort and Gene Expression Omnibus (GEO) dataset, a 5-gene prognostic signature was created. The study underscores loratadine's role in modifying survival outcomes in LUAD patients and suggests potential directions for personalizing treatment. The findings offer insights into the molecular and immunological underpinnings of LUAD, guiding personalized medicine and targeted therapy development. Researchers suggest further exploring this loratadine-based risk score model and its implications for LUAD therapy, supported by immune profiling and the molecular landscape understanding of lung cancer.

Asset Subtitle

Xiwen Liu

Meta Tag

Speaker Xiwen Liu

Topic Tumor Biology – Translational Biology

Keywords

loratadine

lung adenocarcinoma

prognostic model

gene expression

immune profiling

risk score

survival rates

Kaplan-Meier curves

LASSO Cox regression

personalized treatment